Language
English
Publication Date
12-1-2022
Journal
Journal of Functional Foods
DOI
10.1016/j.jff.2022.105356
PMID
36467850
PMCID
PMC9708634
PubMedCentral® Posted Date
11-30-2022
PubMedCentral® Full Text Version
Post-print
Abstract
The clinical study aim was to investigate whether a tannin-based dietary supplementation could improve the efficacy of standard-of-care treatment of hospitalized COVID-19 patients by restoring gut microbiota function. Adverse events and immunomodulation post-tannin supplementation were also investigated. A total of 124 patients receiving standard-of-care treatment were randomized to oral tannin-based supplement or placebo for a total of 14 days. Longitudinal blood and stool samples were collected for cytokine and 16S rDNA microbiome profiling, and results were compared with 53 healthy controls. Although oral tannin supplementation did not result in clinical improvement or significant gut microbiome shifts after 14-days, a reduction in the inflammatory state was evident and significantly correlated with microbiota modulation. Among cytokines measured, MIP-1α was significantly decreased with tannin treatment (p = 0.03) where it correlated positively with IL-1β and TNF- α, and negatively with stool
Keywords
COVID-19, Tannins, Gut microbiota, Dysbiosis, Serum cytokines
Published Open-Access
yes
Recommended Citation
Molino, Silvia; Pisarevsky, Andrea; Badu, Shyam; et al., "Randomized Placebo-Controlled Trial of Oral Tannin Supplementation on COVID-19 Symptoms, Gut Dysbiosis and Cytokine Response" (2022). Faculty and Staff Publications. 5629.
https://digitalcommons.library.tmc.edu/baylor_docs/5629
Graphical Abstract
Included in
Allergy and Immunology Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Clinical Epidemiology Commons, COVID-19 Commons, Pathology Commons